英國利用人工智慧使藥物更安全並減少動物實驗
The UK uses AI to make medicines safer and reduce animal testing
Updated at: June 10, 2026 at 08:30 AM
英國正藉由整合人工智慧來徹底改造醫學研究，以實現藥物開發的現代化。
The UK is transforming its approach to medical research by integrating artificial intelligence to modernize drug development.
作為優先推動合乎道德且與人類相關之科學的國家策略的一部分，英國正積極致力於以先進技術取代傳統的動物實驗。
As part of a national strategy to prioritize ethical, human-relevant science, the UK is actively working to replace traditional animal testing with advanced technologies.
一項關鍵的進展是英國藥品及保健產品管理局(MHRA)於2026年6月啟動的全新監管「沙盒」計畫，這允許研究人員在臨床試驗開始前，利用人工智慧預測藥物在人體內的表現。
A key development is the MHRA's new regulatory 'sandbox,' launched in June 2026, which allows researchers to use AI to predict how medications behave in the human body before clinical trials begin.
目前，90%的藥物在研發過程中失敗，其主因往往是傳統模型無法準確預測人類反應。
Currently, 90% of drugs fail during development, often because traditional models fail to predict human responses accurately.
透過以人工智慧驅動的分析、晶片器官系統以及3D生物列印組織來取代動物試驗，政府旨在降低藥物不良反應所帶來的沉重經濟與個人成本。
By replacing animal trials with AI-driven analysis, organ-on-a-chip systems, and 3D bioprinted tissues, the government aims to reduce the high economic and personal costs of adverse drug reactions.
在7500萬英鎊的資金支持下，英國制定了雄心勃勃的里程碑，包括在2026年前禁止某些針對皮膚與眼睛刺激的動物測試，並計畫在2030年前減少犬類與靈長類動物的研究。
Supported by a £75 million investment, the UK has set ambitious milestones, including banning certain animal tests for skin and eye irritation by 2026 and targeting a reduction in dog and primate studies by 2030.
此轉變不僅是為了動物福祉，更是為了加速提供安全、創新的治療方法，同時將英國定位為現代數據驅動型醫療保健的全球領導者。
This shift is not just about animal welfare; it is a strategic move to accelerate the delivery of safe, innovative treatments while positioning the UK as a global leader in modern, data-driven healthcare.
